• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Diagnostic Testing in Thyroid Cancer: An AJMC® Profiles in Care

Podcast

Michelle Afkhami, MD, from City of Hope, discusses best practices for oncology organizations to leverage molecular/genomic testing, the importance of identifying RET-positive patients early so they can receive targeted treatment, and more.

Diagnostic testing in thyroid cancer is important in order to use biomarkers and quickly identify appropriate treatments for patients.

In this podcast, The American Journal of Managed Care®'s associate editorial director, Mary Caffrey, speaks with Michelle Afkhami, MD, from City of Hope, about best practices for oncology organizations to leverage molecular/genomic testing, the importance of identifying RET-positive patients early so they can receive targeted treatment, and more.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Related Videos
A new study finds law enforcement presence in emergency departments may disrupt care. Lead author Prashasti Bhatnagar discusses policy and training solutions.
Jennifer Snow, MPA, NAMI
Jennifer Snow, MPA, NAMI
Aleata Postell, SVP of pharmacy business development, CenterWell Pharmacy
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Adam Brufsky, MD, PhD, University of Pittsburgh
Dr Steven Manobianco
Roy Mathew, MD, screenshot
Dr Amrita Basu
Danielle Roman, PharmD, BCOP, Allgheny Health Network
Related Content
Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

January 25th 2026
Article

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

Read More

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

January 20th 2026
Podcast

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

The findings reinforce the need for earlier recognition of scarring alopecias—particularly CCCA—and improved education for clinicians. | Image Credit: cattyphoto - stock.adobe.com

CCCA Associated With Longer Time to Diagnosis Vs Other Scarring Alopecias

January 23rd 2026
Article

Central centrifugal cicatricial alopecia (CCCA) faces significant diagnostic delays, highlighting the need for increased awareness and education among providers.

Read More

Managed Care Cast

Managed Care Cast News Roundup: January 13, 2026

January 13th 2026
Podcast

This week's news roundup covers updates in health policy, technology, and access to pharmaceuticals.

Listen

First-line anlotinib plus chemotherapy demonstrates favorable efficacy and manageable toxicity in advanced STS. | Image credit: @Aidman-Adobestock.jpeg

Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma

January 23rd 2026
Article

Phase 2 trial results show anlotinib with anthracyclines and ifosfamide yields a 30.8% ORR and an 82.7% DCR in advanced soft tissue sarcoma.

Read More

A new study highlights how formalized, trauma-informed policies in emergency departments could better protect survivors of violence, said Prashasti Bhatnagar.

How ED Policies Can Better Protect Survivors of Violence: A Q&A With Prashasti Bhatnagar, Esq, MPH

January 23rd 2026
Article

A multistakeholder study explores how law enforcement presence in EDs affects survivors of violence and outlines trauma-informed, patient-centered policy solutions.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.